risperidone has been researched along with Diarrhea in 2 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 9.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 9.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 5.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications." | 5.11 | Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. ( Berry, SA; Eerdekens, E; Eerdekens, M; Lindenmayer, JP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lindenmayer, JP | 1 |
| Eerdekens, E | 1 |
| Berry, SA | 1 |
| Eerdekens, M | 1 |
| Citrome, L | 1 |
| Shope, CB | 1 |
| Nolan, KA | 1 |
| Czobor, P | 1 |
| Volavka, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres[NCT00034775] | Phase 3 | 141 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility[NCT00308360] | Phase 4 | 46 participants | Interventional | 1999-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for risperidone and Diarrhea
| Article | Year |
|---|---|
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Diarrhea; Drug Administration Schedule; Dr | 2004 |
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Diarrhea; Drug Therapy, Combination; Femal | 2007 |